
U.S. Blood Collection Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.

Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The U.S. blood collection market size was estimated at USD 3.2 billion in 2024. The market is expected to grow from USD 3.4 billion in 2025 to USD 5.8 billion in 2034, growing at a CAGR of 6.2%, according to Global Market Insights Inc. The U.S. blood collection industry is growing steadily, driven by an increase in surgical procedures and advancements in blood collection technologies. Additionally, the rising prevalence of chronic and infectious diseases, such as diabetes, cancer, cardiovascular diseases, tuberculosis, and HIV, is playing a significant role in boosting the market's growth.

Blood collection devices are essential tools designed to safely and efficiently draw blood samples for diagnostic testing, transfusions, or research. These devices are a critical part of clinical settings and are widely used in hospitals, laboratories, and blood banks across the U.S. Major companies in the U.S. blood collection industry include Becton, Dickinson and Company, Cardinal Health, and McKesson Corporation. The market primarily focuses on devices such as needles, syringes, vacuum blood collection tubes, lancets, and blood collection sets. These devices are designed to prioritize patient comfort, maintain the integrity of samples, and ensure the safety of healthcare professionals.
The market increased from USD 2.8 billion in 2021 to USD 3.1 billion in 2023. This growth was fueled by increased government initiatives, awareness campaigns, and a growing elderly population that requires frequent diagnostic tests and medical monitoring. Government programs aimed at strengthening public health infrastructure and encouraging preventive care have significantly increased the demand for blood collection services. At the same time, the aging population in the U.S., which is more prone to chronic conditions such as diabetes, cardiovascular diseases, and cancer has led to a rise in routine blood tests. This has driven the adoption of advanced and safer blood collection devices in healthcare settings.
The increasing demand for blood transfusions is a key driver accelerating the growth of the U.S. blood collection market. Blood transfusions play an important role in managing surgical blood loss, traumatic injuries, and various medical conditions, necessitating the use of sterile needles, blood collection bags, and other specialized devices to ensure safety and efficacy. For instance, according to data from the America's Blood Centers, blood transfusion remains one of the most frequently performed procedures in U.S. hospitals.
Blood transfusion ranks as the second most common procedure among patients over 64 and the fifth among those aged 45–64 in U.S. hospitals, underscoring its critical role in geriatric and middle-aged patient care. Further, in 2021 alone, U.S. hospitals transfused approximately 10.76 million units of red blood cells (RBCs), 2.18 million units of platelets, 2.22 million units of plasma, and 1.25 million units of cryoprecipitate AHF, demonstrating the substantial scale and consistent demand within the blood collection and transfusion ecosystem.
Moreover, the rise in the incidence of chronic and infectious diseases such as HIV, tuberculosis (TB), and others has emerged as a key catalyst driving the growth of the U.S. blood collection market. For instance, according to the data from the Centers for Disease Control and Prevention (CDC), approximately 31,800 people acquired HIV in the U.S. in 2022, and 37,981 individuals aged 13 and older received an HIV diagnosis that same year. These conditions often require frequent blood testing for diagnosis, monitoring, and treatment, thereby increasing the demand for safe and reliable blood collection devices.
Blood collection is the process of collecting blood samples for diagnostic, therapeutic, or research purposes. Depending on the test type and the amount of blood needed, samples are collected using either venous or capillary methods. The process involves various tools and devices, such as needles, syringes, lancets, blood collection tubes, and automated systems, to ensure that samples are collected safely, hygienically, and accurately.
| Key Takeaway | Details |
|---|---|
| Market Size & Growth | |
| Base Year | 2024 |
| Market Size in 2024 | USD 3.2 Billion |
| Forecast Period 2025 - 2034 CAGR | 6.2% |
| Market Size in 2034 | USD 5.8 Billion |
| Key Market Trends | |
| Drivers | Impact |
| Increasing incidence of chronic and infectious diseases in U.S. | Drives demand for routine blood testing for conditions such as diabetes, cardiovascular disease, cancer, HIV, and TB, increasing the need for reliable blood collection devices. |
| Rising government initiatives and awareness campaigns | Boosts demand for specialized tubes, micro-containers, and automated collection systems through public health programs and preventive care efforts. |
| Increasing demand for blood transfusions | Sustains high-volume collection needs in hospitals and trauma centers, requiring sterile needles, blood bags, and efficient logistics. |
| Growing geriatric population | Increases demand for minimally invasive, comfort-focused collection tools, especially in home care and long-term care settings. |
| Pitfalls & Challenges | Impact |
| Stringent regulatory challenges | Raises operational complexity for manufacturers. Compliance with sterility, labeling, and traceability standards can delay product development and market entry. |
| Risk of contamination and needlestick injuries | Higher chances of contamination and accidental needle injuries can affect the accuracy of test results, increase the risk of infections for both patients and staff, and drive up healthcare costs especially in busy or understaffed settings where safety protocols may be harder to follow. |
| Opportunities: | Impact |
| Expansion of point-of-care testing | Fuels demand for compact, easy-to-use blood collection devices that support rapid diagnostics in decentralized settings such as clinics, homes, and mobile units. |
| Market Leaders (2024) | |
| Market Leaders |
25% |
| Top Players |
Collective market share in 2024 is 55% |
| Competitive Edge |
|

The U.S. market was valued at USD 2.8 billion in 2021. The market size reached USD 3.1 billion in 2023, from USD 2.9 billion in 2022.
Based on the product type, the U.S. market is segmented into system and consumables. The consumables segment accounted for 76.6% of the market in 2024 due to their precise sample collection and ability to support various types of blood tests. The segment is expected to exceed USD 4.4 billion by 2034, growing at a CAGR of 6.1% during the forecast period. On the other hand, the system segment is expected to grow with a CAGR of 6.6% from 2025 to 2034. The growth of this segment can be attributed to the rising demand for systems that improve efficiency, reduce contamination risks, and enhance patient comfort.
Based on the method, the U.S. blood collection market is segmented into manual blood collection and automated blood collection. The automated blood collection segment accounted for the market share of 46.7% in 2024.
Based on application, the U.S. blood collection market is segmented into diagnostics, treatment, and research. The research segment is expected to grow at a CAGR of 6.2% in the forecast period.

Based on end use, the market is segmented into hospitals and clinics, diagnostic centers, blood banks, and academic and research institutes. The diagnostic centers is expected to grow at a CAGR of 6.6% in the forecast period.
Some of the eminent market participants operating in the blood collection industry include:
Cardinal Health holds a significant share in blood collection market, through its comprehensive product portfolio. It includes Monoject Blue Stopper Blood Collection Tube, Cardinal Health Monoject Grey Stopper Blood Collection Tube, among others.
McKesson Corporation has a strong global workforce of approximately 45,000 employees, which enables the company to drive innovation, and deliver high-quality solutions.
QIAGEN has a robust geographical presence, which enables it to enhance its market reach. Cardinal Health operates over 25 countries, thus comprising of a strong distribution network.
Market, By Product Type
Market, By Method
Market, By Application
Market, By End Use
Key players include Becton, Dickinson and Company, Cardinal Health, McKesson Corporation, Fresenius SE & Co, Terumo Corporation, Abbott Laboratories, Siemens Healthineers, Greiner, Haemonetics Corporation, QIAGEN, Sarstedt AG & Co, Medline Industries, Nipro Corporation, Streck, and Thermo Fisher Scientific.
Becton, Dickinson and Company (BD) led the U.S. blood collection industry in 2024 with a 25% share, leveraging advanced automation and safety-focused devices for hospitals and blood banks.
Diagnostic centers are projected to grow at a 6.6% CAGR during 2025–2034, supported by the increasing number of labs (317,000+ CLIA-registered facilities as of 2024).
Automated blood collection systems held 46.7% of the market share in 2024, valued at about USD 1.5 billion, driven by rising adoption of apheresis, robotic venipuncture, and component separation technologies.
The U.S. market is expected to reach USD 5.8 billion by 2034, supported by the demand for transfusions, government healthcare initiatives, and the expanding geriatric population.
The consumables segment accounted for 76.6% of the market and generated approximately USD 2.45 billion in 2024, driven by high demand for single-use products like tubes, needles, syringes, and blood bags.
The market size was USD 3.2 billion in 2024, with a CAGR of 6.2% expected through 2034, driven by rising surgical procedures, growing chronic disease prevalence, and advancements in blood collection technologies.
The U.S. market is projected to reach USD 3.4 billion in 2025, continuing its steady expansion fueled by chronic disease burden, rising blood transfusion demand, and government health initiatives.


